GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Perkinelmer, Inc. (PKI) [hlAlert]

Rating:
Buy PKI
up 83.92 %

Perkinelmer, Inc. (PKI) rated Buy with price target $57 by Maxim Group

Posted on: Friday,  Jan 31, 2014  8:25 AM ET by Maxim Group

Maxim Group rated Buy Perkinelmer, Inc. (NYSE: PKI) on 01/31/2014. Previously Maxim Group rated Buy Perkinelmer, Inc. (NYSE: PKI) on 03/22/2012.,
when the stock price was $26.88. Since then, Perkinelmer, Inc. has gained 83.93% as of 01/27/2016's recent price of $49.44.
If you would have followed the previous Maxim Group's recommendation on PKI, you would have gained 83.92% of your investment in 1406 days.

Perkinelmer, Inc. is a provider of technology, services and solutions to the diagnostics, academic research, environmental monitoring and safety and security markets. During the fiscal year ended December 28, 2008 (fiscal 2008), the Company operated in two segments: Life and Analytical Sciences, and Optoelectronics. Subsequent to the fiscal 2008, the Company operates in two segments: Human Health and Environmental Health. In January 2009, it acquired Opto Technology Inc. (Opto Technology). In December 2008, the Company acquired Arnel, Inc. (Arnel). In December 2008, it shut down the Cellular Screening Fluorescence and Luminescence workstations business, Analytical Proteomics Instruments business, and Proteomics and Genomics Instruments business. In May 2009, the Company acquired Analytica of Branford, Inc. In September 2009, the Company acquired the genetic screening business of Surendra Genetic Labs, Pvt Ltd. and SYM-BIO Lifescience.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/31/2014 8:25 AM Buy
None
43.60 57.00
as of 10/17/2014
1 Week down  -2.86 %
1 Month down  -9.70 %
3 Months down  -13.08 %
1 YTD down  -2.98 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/24/2013 11:25 AM Buy
None
35.42 43.00
3/22/2012 11:25 AM Buy
None
26.88 33.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy